Merrimack CEO is out as the biotech restructures, chopping its workforce and overhauling R&D
The biotech announced this morning that it is laying off 22% of its workforce — more than 60 staffers based on the 306-member workforce it had at the end of the year. And a big part of the layoffs will fall in R&D and manufacturing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.